Search

Search Constraints

You searched for: Author/Creator Müller‐Tidow, Carsten

Search Results

1. A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. (19th November 2018)

2. A randomized, open‐label, phase I/II trial to investigate the maximum tolerated dose of the Polo‐like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. (16th August 2013)

3. B‐cell maturation antigen‐specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. Issue 8 (30th April 2020)

4. CD33‐directed immunotherapy with third‐generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33‐edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Issue 7 (23rd November 2021)

5. CD7 is expressed on a subset of normal CD34‐positive myeloid precursors. (4th July 2018)

6. CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia. Issue 4 (7th March 2022)

7. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. (2nd February 2021)

9. Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. (13th October 2017)